Ysios Capital
Venture capital
RollingLast verified 10 Nov 2026
Life sciences venture capital firm investing in and creating disruptive biotechnology companies across Europe and the United States.
1 deal in the last 24 months, latest 14 Apr 2026. Derived from its deals in the news.
Key facts
- Stages
- Series C+
- Sectors
- Biotech & pharma
- Eligible countries
- Not stated
- Provider based in
- Spain
- Timing
- Rolling applications
- Focus
- disruptive biotech companies; life sciences
- How to apply
- Apply route unknown
Recent deals
| Company | Round | Sectors | Amount | Role | Announced |
|---|---|---|---|---|---|
| Adcendo ApS | Series C+ | Biotech & pharma, Healthtech | €67.2M | participant | 14 Apr 2026 |
Evidence
Short excerpts from the sources, in their original language, that back the facts above.
- Kind
Leading life sciences investor - Ysios Capital
https://ysioscapital.com/ - Sectors
Improving the life of patients by funding disruptive biotech companies
https://ysioscapital.com/
Status history
- 6 Nov 2026: Rolling (first extraction)
Is something out of date?
Suggest an editTakes 10 seconds
Something else wrong? Report an error.
Work at Ysios Capital? Claim this profile to confirm what you invest in.